StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) stock

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)

Close on Nov 17, 2026Market cap $82.56BP/E –Yield –

Moderna ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Moderna's ebitda for the twelve months ending Jun 30, 2026 was -$3.09B. For fiscal 2025 it was -$2.86B. The highest annual figure on record is $13.53B in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.86B–
FY2024Dec 31, 2024-$3.76B–
FY2023Dec 31, 2023-$3.62B-137.1%
FY2022Dec 31, 2022$9.77B-27.8%
FY2021Dec 31, 2021$13.53B–
FY2020Dec 31, 2020-$732.00M–
FY2019Dec 31, 2019-$515.00M–
FY2018Dec 31, 2018-$388.40M–
FY2017Dec 31, 2017-$248.82M–
FY2016Dec 31, 2016-$208.66M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$759.00M–
Q1 FY2026Mar 31, 2026-$1.33B–
Q4 FY2025Dec 31, 2025-$791.00M–
Q3 FY2025Sep 30, 2025-$209.00M–
Q2 FY2025Jun 30, 2025-$851.00M–
Q1 FY2025Mar 31, 2025-$1.01B–
Q4 FY2024Dec 31, 2024-$1.19B-667.9%
Q3 FY2024Sep 30, 2024-$19.00M–
Q2 FY2024Jun 30, 2024-$1.32B–
Q1 FY2024Mar 31, 2024-$1.23B–
Q4 FY2023Dec 31, 2023$209.00M-87.4%
Q3 FY2023Sep 30, 2023-$1.77B-238.1%
Q2 FY2023Jun 30, 2023-$1.78B-170.4%
Q1 FY2023Mar 31, 2023-$288.00M-106.7%
Q4 FY2022Dec 31, 2022$1.66B-69.8%
Q3 FY2022Sep 30, 2022$1.28B-64.7%
Q2 FY2022Jun 30, 2022$2.52B-19.4%
Q1 FY2022Mar 31, 2022$4.31B+236.1%
Q4 FY2021Dec 31, 2021$5.49B–
Q3 FY2021Sep 30, 2021$3.63B–
Q2 FY2021Jun 30, 2021$3.13B–
Q1 FY2021Mar 31, 2021$1.28B–
Q4 FY2020Dec 31, 2020-$268.00M–
Q3 FY2020Sep 30, 2020-$227.00M–
Q2 FY2020Jun 30, 2020-$114.00M–
Q1 FY2020Mar 31, 2020-$124.00M–
Q4 FY2019Dec 31, 2019-$121.60M–
Q3 FY2019Sep 30, 2019-$123.46M–
Q2 FY2019Jun 30, 2019-$136.21M–
Q1 FY2019Mar 31, 2019-$134.33M–
Q4 FY2018Dec 31, 2018-$145.68M–
Q3 FY2018Sep 30, 2018-$79.32M–
Q2 FY2018Jun 30, 2018-$91.12M–
Q1 FY2018Mar 31, 2018-$72.25M–

More Moderna figures

See a number that looks wrong?